Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 28;14(8):e28503.
doi: 10.7759/cureus.28503. eCollection 2022 Aug.

What Is the Effect of Topiramate Use on Growth in Children With Epilepsy?

Muhammad T Alrifai  1   2   3 , Noura A Alsubaie  2 , Albatool M Abodarahem  2 , Shadan B Alomran  2 , Maryam N Alboqami  2 , Raghad T Alsadun  2 , Yusra Sajid Chachar  4 , Mohammed A Alqassim  1   3 , Mohamed K Abdelkabir  1   3
Affiliations

What Is the Effect of Topiramate Use on Growth in Children With Epilepsy?

Muhammad T Alrifai et al. Cureus. .

Abstract

Objective The literature related to weight loss as a side effect of using topiramate (TPM) in pediatric patients is inconsistent. The aim of this study was to assess the effect of TPM on the growth of pediatric epileptic patients. Methods The electronic medical files of 50 pediatric epileptic patients who were prescribed TPM over 5 years were retrospectively reviewed. Cases treated with other antiepileptic drugs were the control group (n=60). Results Height growth was similar in both groups. At the 6-12-month follow-up, there was a decrease in the average BMI in the TPM group of -0.81 kg/m2 (p=0.019) and an increase in the control group of +0.46 kg/m2 (p=0.023). Weight loss was noted in 21/50 (42%) of the TPM group as compared with 13/60 (22%) in the control group (p=0.02). More weight loss was observed in the overweight TPM group in 7/16 (44%) compared to none in the nine cases in the control group (p=0.03). After the one-year follow-up, the average change in weight was +1.73 kg (p=0.0001) and +3.53 kg (p=0.0001) in the TPM and control groups, respectively. In patients with normal initial BMI, the weight increased by +1.3 kg on average, compared to the group with a high initial BMI, which decreased by -2.55 kg. Conclusion Topiramate use has no negative effect on height growth in pediatric patients with epilepsy. While mild weight loss occurs frequently in the first year of treatment, weight gain resumes after the first year except in patients with a high initial BMI.

Keywords: body mass index: bmi; epilepsy; kingdom of saudi arabia (ksa); topiramate; weight.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. ILAE official report: a practical clinical definition of epilepsy. Fisher RS, Acevedo C, Arzimanoglou A, et al. Epilepsia. 2014;55:475–482. - PubMed
    1. Incidence and prevalence of childhood epilepsy: a nationwide cohort study. Aaberg KM, Gunnes N, Bakken IJ, et al. Pediatrics. 2017;139:0. - PubMed
    1. Topiramate monotherapy in newly diagnosed epilepsy in children and adolescents. Glauser TA, Dlugos DJ, Dodson WE, Grinspan A, Wang S, Wu SC. J Child Neurol. 2007;22:693–699. - PubMed
    1. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G. Neurology. 1999;52:1338–1344. - PubMed
    1. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, Pledger G. Neurology. 1999;52:1330–1337. - PubMed

LinkOut - more resources